Cargando…

Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

SIMPLE SUMMARY: Determining the most sensitive imaging technique to evaluate neuroendocrine tumors spread may have an impact on therapeutic management. The aim of this multicentric study was to prospectively assess (68)Ga-DOTANOC PET/CT sensitivity compared to the combination of multiphasic CT, soma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lugat, Alexandre, Frampas, Éric, Touchefeu, Yann, Mirallié, Éric, Bras, Maëlle Le, Senellart, Hélène, Rauscher, Aurore, Fleury, Vincent, Campion, Loïc, Rohmer, Vincent, Couturier, Olivier-François, Lebtahi, Rachida, Rouzet, François, Ruszniewski, Philippe, Kraeber-Bodéré, Françoise, Bourgeois, Mickaël, Ansquer, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856693/
https://www.ncbi.nlm.nih.gov/pubmed/36672462
http://dx.doi.org/10.3390/cancers15020513
_version_ 1784873695484837888
author Lugat, Alexandre
Frampas, Éric
Touchefeu, Yann
Mirallié, Éric
Bras, Maëlle Le
Senellart, Hélène
Rauscher, Aurore
Fleury, Vincent
Campion, Loïc
Rohmer, Vincent
Couturier, Olivier-François
Lebtahi, Rachida
Rouzet, François
Ruszniewski, Philippe
Kraeber-Bodéré, Françoise
Bourgeois, Mickaël
Ansquer, Catherine
author_facet Lugat, Alexandre
Frampas, Éric
Touchefeu, Yann
Mirallié, Éric
Bras, Maëlle Le
Senellart, Hélène
Rauscher, Aurore
Fleury, Vincent
Campion, Loïc
Rohmer, Vincent
Couturier, Olivier-François
Lebtahi, Rachida
Rouzet, François
Ruszniewski, Philippe
Kraeber-Bodéré, Françoise
Bourgeois, Mickaël
Ansquer, Catherine
author_sort Lugat, Alexandre
collection PubMed
description SIMPLE SUMMARY: Determining the most sensitive imaging technique to evaluate neuroendocrine tumors spread may have an impact on therapeutic management. The aim of this multicentric study was to prospectively assess (68)Ga-DOTANOC PET/CT sensitivity compared to the combination of multiphasic CT, somatostatin receptor scintigraphy and MRI to evaluate whether this imaging modality results in therapeutic modifications. We confirm in a homogenous population of 105 grade 1 or 2 gastroenteropancreatic neuroendocrine tumors the higher sensitivity of (68)Ga-DOTANOC PET/CT in per-patient and per-region analysis, as well as in the detection of primary tumor and small lesions such as peritoneal carcinomatosis and bone lesions leading to an impact on therapeutic management of almost half of the patients. ABSTRACT: The aim of this multicentric study was to prospectively compare (68)Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by (68)Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. (68)Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). (68)Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of (68)Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs.
format Online
Article
Text
id pubmed-9856693
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98566932023-01-21 Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET Lugat, Alexandre Frampas, Éric Touchefeu, Yann Mirallié, Éric Bras, Maëlle Le Senellart, Hélène Rauscher, Aurore Fleury, Vincent Campion, Loïc Rohmer, Vincent Couturier, Olivier-François Lebtahi, Rachida Rouzet, François Ruszniewski, Philippe Kraeber-Bodéré, Françoise Bourgeois, Mickaël Ansquer, Catherine Cancers (Basel) Article SIMPLE SUMMARY: Determining the most sensitive imaging technique to evaluate neuroendocrine tumors spread may have an impact on therapeutic management. The aim of this multicentric study was to prospectively assess (68)Ga-DOTANOC PET/CT sensitivity compared to the combination of multiphasic CT, somatostatin receptor scintigraphy and MRI to evaluate whether this imaging modality results in therapeutic modifications. We confirm in a homogenous population of 105 grade 1 or 2 gastroenteropancreatic neuroendocrine tumors the higher sensitivity of (68)Ga-DOTANOC PET/CT in per-patient and per-region analysis, as well as in the detection of primary tumor and small lesions such as peritoneal carcinomatosis and bone lesions leading to an impact on therapeutic management of almost half of the patients. ABSTRACT: The aim of this multicentric study was to prospectively compare (68)Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by (68)Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. (68)Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). (68)Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of (68)Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs. MDPI 2023-01-14 /pmc/articles/PMC9856693/ /pubmed/36672462 http://dx.doi.org/10.3390/cancers15020513 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lugat, Alexandre
Frampas, Éric
Touchefeu, Yann
Mirallié, Éric
Bras, Maëlle Le
Senellart, Hélène
Rauscher, Aurore
Fleury, Vincent
Campion, Loïc
Rohmer, Vincent
Couturier, Olivier-François
Lebtahi, Rachida
Rouzet, François
Ruszniewski, Philippe
Kraeber-Bodéré, Françoise
Bourgeois, Mickaël
Ansquer, Catherine
Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
title Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
title_full Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
title_fullStr Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
title_full_unstemmed Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
title_short Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
title_sort prospective multicentric assessment of (68)ga-dotanoc pet/ct in grade 1-2 gep-net
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856693/
https://www.ncbi.nlm.nih.gov/pubmed/36672462
http://dx.doi.org/10.3390/cancers15020513
work_keys_str_mv AT lugatalexandre prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT frampaseric prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT touchefeuyann prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT mirallieeric prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT brasmaellele prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT senellarthelene prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT rauscheraurore prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT fleuryvincent prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT campionloic prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT rohmervincent prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT couturierolivierfrancois prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT lebtahirachida prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT rouzetfrancois prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT ruszniewskiphilippe prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT kraeberboderefrancoise prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT bourgeoismickael prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet
AT ansquercatherine prospectivemulticentricassessmentof68gadotanocpetctingrade12gepnet